Objective: The presence of synchronous multiple primary non-small-cell lung cancers (SMPLC) is a rare condition and the optimal treatment remains unclear. In this study, the survival of surgically treated SMPLC patients and the factors affecting survival were analyzed. Methods: Between 2001 and 2008, 26 consecutive patients diagnosed with SMPLC, who had all of their tumors resected, were retrospectively evaluated. Patients, who had bronchoalveolar carcinoma or carcinoid tumors and satellite nodules, were excluded. Prognostic factors were analyzed using univariate and multivariate analyses. Results: The tumors were unilateral in 14 and bilateral in 12 patients. In total, 38 procedures were performed. A complete resection was achieved in 35 (92.1%) procedures. The in-hospital mortality rate was 7.6% (two patients). The overall 5-year survival rate was 49.7%, and the median survival time was 40 months. The 5-year survival rate was 40.6% for unilateral and 62.8% for bilateral SMPLC patients ( p = 0.47). Histopathologic tumor type, N1 nodal disease, tumor (T) status, and older age did not influence survival. There was no survival disadvantage for patients, upon whom a sublobar resection had been performed. There was a trend toward poorer survival in patients upon whom a pneumonectomy had been performed ( p = 0.12). The 3-year survival rate for patients, who received adjuvant chemotherapy and/or radiotherapy (66.7%), was better than other patients (56.3%). In the multivariate analysis, we found a trend toward poor survival in patients, who received a pneumonectomy, and a trend toward better survival in patients, who received adjuvant therapy ( p = 0.05 and p = 0.06). Conclusions: The survival of SMPLC patients, who were treated surgically, was satisfactory. Pneumonectomy was a poor prognostic factor, whereas adjuvant therapy was a good prognostic factor. #
Introduction
A second cancer may exist in the ipsilateral or contralateral lung at the time of diagnosis of a primary lung cancer. The second cancer may be a metastasis of the primary cancer, or a cancer of another organ, or it can be a synchronous primary lung cancer [1, 2] . Multiple primary lung cancers diagnosed at the same time are called synchronous multiple primary lung cancers (SMPLC) [1, 2] . SMPLC is a rare entity, but there has been a gradual increase in the number of patients diagnosed with SMPLC as a result of advances in the diagnostic methods [3] [4] [5] .
Studies considering an approach to a patient with synchronous primary lung cancers are scarce, and there is a considerable variation in the survival results [2] . Possible causes for this variability include difficulty in establishing an SMPLC diagnosis, inclusion of patients with bronchoalveolar carcinoma, carcinoid tumors or satellite nodules, weaknesses in assessments due to small sample size, or the second cancer being a metastasis of the primary cancer [6] [7] [8] [9] . In many studies, therapeutic methods implemented in SMPLC patients are not homogeneous [4, 5] . Thus, there is no universal agreement as to which diagnostic and therapeutic methods need to be followed in SMPLC cases.
In the present study, we addressed the diagnostic methods and surgical approaches in patients with SMPLC, explored the efficacy of surgical treatment and the factors affecting survival in patients treated with surgery.
Materials and methods
Between January 2001 and December 2008, among 1355 patients, who underwent surgical resection for non-smallcell lung cancer (NSCLC) in our clinic, we found 102 (7.5%) patients having synchronous multiple lung cancers. We investigated the SMPLC patients. SMPLC diagnosis was based on the criteria of Martini-Melamed [11] and Antakli [12] ( Table 1) . Cases with metastases to the mediastinal lymph nodes identified after thoracotomy (n = 2), and cases with unilateral tumors of the same cell type and interlobar-lymph node involvement (n = 4) were excluded. However, cases with a satellite tumor (regardless of tumor (T) and node (N) status, tumors with the same histopathological type in the same lobe, n = 29), low-grade tumor (n = 2), bronchoalveolar carcinoma (n = 5), or metachronous cancer (n = 34) were also excluded. SMPLC was diagnosed in 26 patients. Medical case files of these patients were reviewed retrospectively. Tumornode metastasis (TNM) staging of the patients was conducted according to the sixth staging system criteria [10] . Age, sex, pulmonary function test (PFT) results, tumor location, type of lung resection, completeness of the lung resection, histopathologic tumor type, T and N status, and existence of adjuvant therapy were analyzed as variables.
The Ethics Board of our hospital decided that there was no need to obtain informed consent from the patients because this was a retrospective study, and the identities of the patients would not be disclosed.
All patients were evaluated by chest X-ray and computed tomography (CT) of the thorax and upper abdomen. Routine biochemical tests and PFTs were performed. Carbon-monoxide diffusing capacity, perfusion scintigraphy of the lung, 6-min walking test, stair-climbing test, and the maximal oxygen consumption test, when necessary, were conducted in patients with borderline PFT. All patients had been evaluated by fiber optic bronchoscopy (FOB). All patients with multiple cancers identified after 2005 also underwent auto-fluorescent bronchoscopy and/or narrow-band bronchoscopy. Positron emission tomography (PET-CT) had been requested in all patients. A total of 21 cases had magnetic resonance imaging (MRI) and five cases had a CT to screen for cranial metastases.
There were unilateral synchronous cancers in 14 cases and bilateral SMPLC in 12 cases. Twenty-four cases had two synchronous primary tumors, and two cases had three. Among the 14 unilateral SMPLC patients, seven were diagnosed preoperatively, four perioperatively, and three postoperatively by pathological examination.
Histopathological diagnosis of the pulmonary tumor on one side was established by FOB or transthoracic fine needle aspiration biopsy (TTFNAB) in all 12 bilateral SMPLC cases. Diagnosis of the contralateral tumor was made by preoperative FOB or TTFNAB in seven cases, by video-assisted thoracoscopic surgery (VATS) in three cases, and by limited thoracotomy in two cases.
A standard mediastinoscopy was performed for mediastinal staging in all cases. The mean number of lymph node samples taken during the mediastinoscopy was 3.6. Moreover, additional procedures were conducted in the same session in four cases: lymph node sampling by VATS, extended mediastinoscopy, and mediastinotomy were performed in two, one, and one of these cases, respectively.
Surgical approaches
A. Surgical approach in patients with a unilateral synchronous tumor ( Fig. 1) : Mediastinal, hilar, and interlobarlymph nodes were dissected and sent for frozen section (F/S) examination in all cases when multiple tumors were diagnosed pre-or perioperatively. Lymph node involvement and histopathological tumor type were assessed intra-operatively. The surgery was continued in cases with suspected SMPLC. The type of lung resection was determined after assessing pulmonary functions and the size and location of the tumors. B. Surgical approach in patients with bilateral synchronous tumors ( Fig. 2 ):
(i) When the diagnosis of tumors on both sides was known In these cases, thoracotomy or VATS was performed first on the side of the tumor with a more advanced stage, followed by resection after intraoperative staging.
(ii) When the diagnosis of the tumor in one lung was unknown These were cases in which a lung cancer was diagnosed in one lung and another suspected malignancy was detected in the contralateral lung by CT or PET-CT, but the diagnosis had not been established. Following the mediastinoscopy, both diagnostic and therapeutic interventions were planned for the unknown tumor. Three peripherally located T1-sized tumors, and two larger and deeply located tumors were sampled or totally excised with VATS and a muscle-sparing thoracotomy, respectively, and the specimens were sent for F/S. Mediastinal, hilar, and interlobar-lymph ganglia on the affected side were sampled and examined intra-operatively in cases diagnosed with NSCLC. A lung resection was performed based on the pulmonary functions.
After the waiting period, patients with bilateral SMPLC underwent a thoracotomy on the contralateral side and received the appropriate pulmonary resection. The median waiting period in these patients was 36.5 days (range, 6-67 days). All patients underwent biochemical tests and a complete blood count (CBC). A new thoracic CT was taken from patients, who had a waiting period longer than 4 weeks. Prior to resection on the contralateral side, all patients were re-evaluated with a new PFT. According to the new PFT, criteria for fitting for planned lung resection were used. The PFT was repeated after 1 week when it showed limited pulmonary function. A sublobar resection was performed on patients with limited PFT.
Adjuvant chemotherapy (ChT) was routinely advised after year 2005 for all N1 patients, but also advised for all the patients included in the study due to the existence of SMPLC. With the exception of two cases, who died, all patients were referred to an oncologist for postoperative adjuvant ChT/radiotherapy (RT). Of the 24 surviving patients, 18 had adjuvant ChT with or without RT. Five patients could not tolerate ChT, and one patient was considered unsuitable for adjuvant treatment due to advanced age and limited PFT.
All patients were scheduled for clinical and radiological follow-up. The median follow-up period was 20 months (range, 0-98 months). Patients were assessed quarterly in the first 2 years, and biannually thereafter, by taking a history, a physical examination, and a chest X-ray. Laboratory tests and advanced radiological methods were requested if there were any symptoms.
Data were analyzed with the Statistical Package for Social Sciences (SPSS) statistical package (SPSS Inc., Chicago, IL, USA). The x 2 or Fisher's exact test were used to compare group frequencies. The Mann-Whitney U test was used to compare continuous variables. The day of thoracotomy in patients, who had one operation, and the day of the second thoracotomy in patients, who had two operations, was taken as time zero. The day a patient died was used as the end point. Patients, who died in the hospital, were included in the survival analysis. Survival was determined univariately using Kaplan-Meier method. Survival differences were compared with the log-rank test. Factors that affected survival in the univariate analysis at a p < 0.3 level were included in a multivariate analysis. Multivariate analysis was assessed by the Cox proportional hazards model. The significance level was set at p < 0.05.
Results
All patients included in the study were males, with a mean age of 59.6 years (range, 48-77 years; Table 2 ). At the time of diagnosis, 24 (92%) patients were smokers, and the mean forced expiratory volume in 1 s (FEV 1 ) was 2287 ml (76% of predicted) (range, 1200-3550 ml, 67-110% of predicted).
Histopathological tumor types were the same in seven and different in seven unilateral SMPLC cases (Table 2) . Two patients with unilateral SMPLC had three lung cancers. In the first case, two tumors were in the right-upper lobe (T1 squamous and T2 adenocarcinoma) and one was in the superior segment of the right-lower lobe (T1 adenocarcinoma), with N0 status. The other case had two squamous cell cancers (T1 and T2) in the left-upper lobe and an adenocarcinoma (T1) in the left-lower lobe; no lymph node metastasis was found. There was N1 lymph node involvement in seven of the unilateral SMPLC cases, though none of the cases had hilar or interlobarlymph node involvement. The types of lung resections performed are given in Table 2 . Reasons for pneumonectomy were that the tumors were in two lobe locations in 10 patients (seven in the left lung and three in the right lung) with unilateral SMPLC; and in one of the patients, the tumor was in the central location; the remaining patients had bilateral SMPLC. Resection of the thoracic wall was required in three unilateral SMPLC cases. A complete resection was achieved in 13 (92.8%) cases. The median postoperative hospitalization period was 10 days (range, 5-28 days).
The histopathological tumor types were the same in 10, and different in two bilateral SMPLC cases (Table 2 ). Both tumors in three cases had no lymph node metastasis (N0), and one of the tumors had N1 lymph node metastasis in nine cases. A total of 24 resections were performed in 12 patients. In addition to the lung resection, one case received pulmonary artery patch plasty, one had a thoracic wall resection, and three of the lobectomies were performed as bronchial sleeve resections. In 22 of the 24 procedures (91.6%) performed in 10 of the 12 patients (83.3%), the procedures were complete; whereas the procedures were microscopically incomplete in the second operations of two patients. Morbidity and mortality ratios are presented in Table 2 . The median postoperative hospitalization period was 8 days (range, 3-13) for the first operation and 8 days (range, 6-13) for the second operations ( p = 0.27).
There was no statistically significant difference in morbidity between unilateral and bilateral SMPLC cases ( p = 0.72). There was also no difference between FEV 1 levels of patients, who did or did not develop complications ( p = 0.81). There was no statistically significant difference in morbidity between patients, who had a standard resection, and those, who received an extended resection ( p = 0.12). This was true for patients, who had a pneumonectomy, and for other patients as well ( p = 0.42).
Recurrence was noted in eight cases during follow-up (five unilateral and three bilateral SMPLC patients), seven of whom had had postoperative adjuvant treatment and one had not. Local recurrence occurred in three cases at postoperative months 7, 8, and 15, and these patients received RT. Two of the patients died 4 and 11 months after recurrence developed, whereas another patient is at postoperative month 71, and currently under follow-up, with no problem. Distant metastases were identified in four cases at postoperative months 7, 8, 16, and 30. Two had RT and one had ChT. One patient could not be given treatment due to poor health status. These patients died 3-10 months after diagnosing the distant metastasis. In one case, local recurrence was detected at postoperative month 12, and the patient was given RT. The same patient had a cerebral metastasis at postoperative month 32, and died 2 months later. There was no significant difference in recurrence between patients who had been performed a wedge resection of one tumor and those who had been performed another type of resection for both tumors ( p = 0.33). There was no significant difference in recurrence between patients who had been performed a wedge resection or a segmentectomy of one tumor combined, and those who had been performed other types of resections for both tumors ( p = 1).
The 5-year Kaplan-Meier survival in 26 SMPLC cases was 49.7% (median, 40 months, Fig. 3 ). The 5-year survival in the unilateral and bilateral SMPLC cases was 40.6% and 62.8%, respectively ( p = 0.47, Fig. 4 ). Advanced age (70 years and [ over) did not affect survival ( p = 0.76). T size or the presence of N1 involvement also had no effect on survival ( p = 0.64 and p = 0.40, respectively).
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Anatomical resection was performed in all unilateral SMPLC cases. In the bilateral SMPLC cases, we did not find a significant difference in 5-year survival between patients who had been performed a limited lung resection (wedge) for at least one of the tumors and those who had been performed an anatomical resection (extended segmentectomy/lobectomy) for both tumors ( p = 0.49).
The 5-year survival rates in patients who had been or had not been performed a pneumonectomy were 27% and 71.1%, respectively ( p = 0.12, hazard ratio (HR), 2.84; 95% confidence interval (CI), 0.7-11.42, Fig. 5 ). Patients who had been performed a standard resection and those who had been performed an extended resection did not differ in terms of survival ( p = 0.92).
Of the 54 tumors, 38 (70.4%) tumors in 26 patients were squamous, 15 (27.8%) tumors were adenocarcinoma, and one (1.8%) tumor was a large-cell carcinoma. The histopathological types of tumors were the same in 65% of the cases. The 5-year survival was 78% when the histopathological tumor types were different, and 25% when they were identical ( p = 0.20, HR, 0.38; 95% CI, 0.07-1.83).
The 3-year survival among patients, who did not have adjuvant ChT and/or RT, was 56.3%, whereas 3-and 5-year survival rates in patients, who had ChT and/or RT, were 66.7% and 53.4%, respectively ( p = 0.28).
The multivariate analysis showed that there was a trend toward a poor prognosis in patients, who received a pneumonectomy ( p = 0.05, HR, 1.68; 95% CI, 0.96-30.2), whereas there was a better prognosis in patients, who received adjuvant treatment ( p = 0.06; HR, 1.8; 95% CI, 0.88-41.97).
Discussion
It is disconcerting to identify more than one lung cancer in a patient at the time of diagnosis. Both tumors may be primary lung cancers (SMPLC) that developed independently, and it can be argued that they are independent tumors when they have different histopathological types. However, if both tumors have the same histopathological type, one of the tumors is primary and the other is the metastasis, or both the tumors are SMPLC that developed independently. In the sixth and seventh lung cancer TNM staging systems, the presence of SMPLC is not classified as a separate entity, but rather, one tumor is the metastasis of the other [10, 13] . The seventh TNM staging system suggested that tumors in the same lung, but different lobes, should be considered as T4. This assessment was based on 180 cases, and some of the cases had bronchoalveolar cancer. However, carcinoid tumors and bronchoalveolar cancers should not be included in SMPLC [1, 5] . Nodules in the contralateral lung were suggested to be considered M1a; however, the assessment was based on 362 bilateral SMPLC cases and only seven cases had bilateral surgery. Therefore, defining the status as M1a is open to debate [13] .
Numerous surgeons have used the criteria set by MartiniMelamed and Antakli to diagnose SMPLC. However, there is ambiguity among these criteria with regard to satellite tumors. According to these criteria, the presence of tumors in a lobe with the same cell type in different segments (should the other criteria be fulfilled) was ruled in favor of SMPLC. However, Detterbeck et al. [1] argued that such tumors are not likely to be SMPLC, and that these tumors were most probably satellite tumors, because survival was generally good. These tumors were classified as T3 in the seventh TNM staging system due to good survival [13] . In the present study, these tumors were considered satellite tumors and were excluded from the study.
If the tumors are of the same histopathological type, the most accurate method to diagnose both the tumors as primary tumors would be to compare their molecular and genetic characteristics. However, such examinations can be done in few centers. Thus, the Martini-Melamed and Antakli criteria should be used to diagnose SMPLC, but tumors with the same histopathological type should be considered satellite tumors, and not be included in SMPLC if they occur in the same lobe.
Diagnosing SMPLC is rather difficult when the histopathological types are the same. In the majority of multiple lung cancer studies, patients with all of the possibilities stated above were included. Because these groups are not homogenous SMPLC patients, they would not be totally reliable for drawing conclusions. In the present study, we stratified the patients from a series of patients that we homogenized as much as possible and tried to examine the efficacy of surgical treatment in SMPLC patients and determine the factors that affected survival. Thus, patients with satellite tumors (tumors with the same histopathological type in the same lobe, regardless of T and N status), unilateral tumors with the same cell type in the presence of interlobar-lymph node involvement, low-grade tumors, bronchoalveolar carcinoma, metachronous cancers, and metastasis to the mediastinal lymph node identified before or after thoracotomy, and patients whose tumors could not be resected totally were not included in the present study.
It is not clear whether patients with SMPLC would benefit from surgical treatment or who would benefit, because there are contradictory results in the literature with regard to survival in patients with synchronous tumors [4, 12] . While Adebonojo did not consider 5-year survival following surgery among his patients [14] , Mingyon and Tadasu reported a 75.8% 5-year survival in patients with bilateral synchronous tumors [7] . Possible sources for the discrepancy in these results are the heterogeneity in the patient population and treatment modalities. In our series, the general survival ratio in unilateral and bilateral SMPLC cases indicated that SMPLC patients should not be denied the opportunity for surgical treatment.
The goal of surgery is to conduct a total resection; however, the type of resection depends on the T and N status and pulmonary reserves [1, 15, 16] . Despite indications for extending the resection, some surgeons opt for a limited resection, prompted by concerns that the pulmonary reserve may be insufficient [1, 16] . In some SMPLC cases, other procedures may be required, in addition to standard surgical lung resection, to achieve a complete resection. In our series, surgical procedures other than lung resection were performed in eight cases, and there were no significant differences in morbidity or survival. Thus, extended resections can also be performed in SMPLC patients with good cardiac and pulmonary reserves to achieve a complete resection.
Five-year survival in patients, who did or did not have a pneumonectomy, were 27% and 71.1%, respectively, but this difference was not statistically significant ( p = 0.12). In the multivariate analysis, no statistically significant effect was found in patients, who received a pneumonectomy, but a trend toward poor prognosis was revealed. We think that a significant effect could be found if there were more patients. A pneumonectomy, with poorer survival ratios, is more risky than a lobectomy [17, 18] . Thus, parenchyma-sparing operations are more frequently performed. We also tried to avoid pneumonectomy as much as possible. However, the type of resection had no effect on survival. Thus, a segmentectomy or a lobectomy may be a good alternative if complete resection is achieved.
In the present study, an anatomical resection was conducted in all unilateral SMPLC cases. In the bilateral SMPLC cases, there was no significant difference in survival between patients, who had limited resection of at least one of the tumors, and those who had anatomical resection of both tumors. Although Lerut et al. [4] found no difference in survival between patients, who had anatomical and limited resections, performing an anatomical resection is advisable, except in patients with limited pulmonary reserves.
In patients with bilateral SMPLC, as Ferguson reported [19] , there is an agreement that, sequential resection starting with the most advanced lesion is appropriate, if the two tumors are diagnosed as cancer preoperatively. That was our approach too. However, it is difficult to perform an anatomical resection on the contralateral side after a pneumonectomy. While a right superior lobectomy can be performed following a left pneumonectomy, only a segmentectomy or a wedge resection can be undertaken after a right pneumonectomy [16, [20] [21] [22] . However, these studies included a small number of patients, and many of them were undertaken for metachronous lung cancer or metastases. In these studies, respiratory and cardiac morbidities after the operation had been reported as higher than expected. Hence, when the cancer diagnoses for both sides are known, priority can be given to the side with the smaller tumor if a pneumonectomy on the contralateral side is required due to a reason such as fissure invasion; but it is not expected to be inoperable after the first resection. In that case, performing a contralateral pneumonectomy is safer and easier than performing an additional resection on a patient, who has received a pneumonectomy. We did not have such a case in our series, but there was a patient, who had a right pneumonectomy due to fissure invasion and wedge resection on the contralateral side because an anatomical resection could not be performed on the contralateral side during the second operation. The tumor recurred locally at the wedge resection site in this patient at 15 months.
In bilateral SMPLC cases, the priority for operation should be given to the side of the undiagnosed tumor, when the tumor type on one side is unknown [5] . In such cases, we gave the priority for diagnosis and treatment to the side without the diagnosis.
There is no universal agreement as to how long patients with bilateral SMPLC should wait before the second operation, but a 4-6-week waiting period has been suggested [1, 15] . During the waiting period, the surgeon can determine whether the patient is ready for the operation by completing a physical examination and cardiopulmonary tests. The median waiting period in the present study was 36.5 days (range, 6-67 days), consistent with literature reports.
In unilateral and bilateral SMPLC cases, the second tumor has the potential to be the metastasis of the first if the histopathological tumor types are the same [2] . Thus, survival is expected to be low. If a second tumor is detected in a separate lobe during the operation, the second tumor can be accepted as a synchronous tumor, if there is no mediastinal lymph node involvement and systemic metastasis is not suspected [1] [2] [3] . In such cases, we examined the interlobar-lymph nodes, and classified cases that had positive involvement at station #11 and had resection as an SMPLC (because the possibility of metastasis was higher due to involvement of the common lymphatic pathways).
We found that histopathological type did not have a significant effect on survival. This result can be attributed to the exclusion of patients with satellite tumors, tumors that were in the same lobe and had the same histopathological type as the first tumor, and exclusion of patients with two tumors in different lobes but of the same histopathology and who had interlobar-lymph node involvement. Among bilateral SMPLC cases, Lerut et al. reported no difference in survival between patients with the same or different histopathologies [4] .
The multivariate analysis revealed that adjuvant ChT and/or RT tended to have positive effects on survival. Trousse et al. reported a similar result [18] . Despite an effort to exclude tumors other than SMPLC and meticulous treatment in the SMPLC cases, it is always possible that some cases will actually be metastases and, in theory, adjuvant treatment would be helpful for treating distant metastasis. However, there is no broad consensus on which patients should receive adjuvant treatment and, how it should be given. [23] . In conclusion, the present study demonstrated beneficial effects of adjuvant treatment on survival, but further comparative studies are required.
There is ongoing debate on the diagnosis, treatment, and staging of SMPLC and the results of studies are contradictory due to heterogeneous sample groups. More studies on SMPLC are required to reach a consensus. The present study showed that surgical resection can be performed with low morbidity/ mortality and has beneficial effects on survival. Segmentectomy may be preferred in patients with limited pulmonary reserves. It is necessary to avoid a pneumonectomy in SMPLC patients. Postoperative adjuvant treatment has favorable effects on treatment.
